Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanomedicine CompanyNanobiotix Elects Former Sanofi-Aventis Oncology Researcher Elsa Borghi, MD, as its Medical Director

Abstract:
Podcast available at www.medtechmatters.com

Nanomedicine CompanyNanobiotix Elects Former Sanofi-Aventis Oncology Researcher Elsa Borghi, MD, as its Medical Director

PARIS, France | Posted on May 27th, 2008

Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that it has appointed Elsa Borghi, MD, as medical director.

Previously, Dr. Borghi worked in the R&D oncology department for Sanofi-Aventis, one of the five largest pharmaceutical companies in the world, until the onset of 2008, when she joined Nanobiotix. She has lead successful clinical trials worldwide for major drugs and registration in the Oncology field. Dr. Borghi began working in the pharmaceutical industry in 1996 on drug safety and international reporting, mainly for oncology and cardiovascular drugs. She began working on pivotal cancer clinical trials in 1999, including early colon cancer, early- and late-stage breast cancer, and prostate cancer, for which she was responsible for a chemotherapy product registration. In addition, Dr. Borghi has worked on soft tissue sarcoma, lung cancer and phase I studies for chemotherapies, antisense and targeted therapies. Most of her recent work was focused on tumor perfusion modifiers such as antivascular agents. Dr. Borghi obtained her medical degree from the University of Cordoba School of Medicine in March 1984 and the French equivalent in 1994 from the University of Paris V.

"The appointment of such an experienced clinical manager and scientific researcher as Dr. Borghi is a very significant milestone for Nanobiotix," said Laurent Levy, Ph.D., chief executive officer of Nanobiotix. "With strong preclinical work behind us, we are looking forward to the next giant step for Nanobiotix, our first-in-man and the start of clinical trials in the not-too-distant future. We therefore expect to benefit from Dr. Borghi's substantial accomplishments related to turning promising research into approved products designed to produce favorable outcomes for patients."

####

About Nanobiotix
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™ - a technology platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy’s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of x-ray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance—not a drug—that can subsequently be activated in order to locally (intratumor) increase the dose of x-ray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard x-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

For more information, please click here

Contacts:
Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Nanomedicine

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Announcements

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project